Biotech partner recognizes strength of Willow’s first in class FutureGrownTM technology platform for producing natural products Further expansion and diversification
Rapid success of first collaboration leads to partnership on high-value specialty ingredient Enzyme development expected to enable commercial-scale production in
Mountain View, California – May 12, 2023 – Willow Biosciences Inc.(“Willow” or the “Company“) (TSX: WLLW; OTCQB: CANSF) is pleased to
Starts off year with significant commercial momentum toward focus on delivering robust year-over-year revenue growth for 2023 Previous steps taken
Commercial agreement follows the early success on the development phase of the UDCA program with Sandhill One Solid execution on
Complements Company’s significant expertise in existing strain engineering and precision fermentation Offers commercial partners more rapid product innovation at significantly
Phone: +1 403 910 5140
Email: info@willowbio.com
© 2023 Willow Biosciences Inc.
Powered by BragDeal Inc.
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.